Evidence map›Paper›PMID 31184979›Full record

ArticleHuman vaccines & immunotherapeutics2019

Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study.

Shelly Bolotin, Alberto Severini, Todd Hatchette, Elizabeth McLachlan, Rachel Savage, Stephanie L Hughes, John Wang, Shelley L Deeks, Sarah Wilson, Marc Brisson and 6 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Measles surveillance in Canada, 2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shelly BolotinPublic Health Ontario, Toronto, ON, Canada.
Alberto SeveriniNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Todd HatchetteDepartment of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, NS, Canada.ORCID 0000-0002-5377-2528
Elizabeth McLachlanNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.ORCID 0000-0001-6967-794X
Rachel SavagePublic Health Ontario, Toronto, ON, Canada.
Stephanie L HughesPublic Health Ontario, Toronto, ON, Canada.ORCID 0000-0002-6708-3731
John WangPublic Health Ontario, Toronto, ON, Canada.
Shelley L DeeksPublic Health Ontario, Toronto, ON, Canada.
Sarah WilsonPublic Health Ontario, Toronto, ON, Canada.ORCID 0000-0002-8239-0094
Marc BrissonDépartement de médecine sociale et préventive, Université Laval, Québec City, QC, Canada.
Scott A HalperinDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Jonathan GubbayPublic Health Ontario, Toronto, ON, Canada.
Tony MazzulliPublic Health Ontario, Toronto, ON, Canada.
Bouchra SerhirLaboratoire de santé publique du Québec/Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, Canada.ORCID 0000-0003-0735-0452
Brian J WardDepartment of Microbiology and Immunology, McGill University, Montreal, QC, Canada.ORCID 0000-0003-3251-958X
Natasha CrowcroftPublic Health Ontario, Toronto, ON, Canada.ORCID 0000-0002-6761-8783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canada eliminated measles in 1998. We conducted a sero-epidemiology study to estimate population immunity to measles in the province of Ontario, Canada and to identify groups at higher risk of outbreaks. We used a previously developed modified enzyme immunoassay to test 1,199 residual sera from patients aged 1-39 years. We re-tested negative and equivocal sera using a plaque reduction neutralization assay. We interpreted our results in the context of Ontario's immunization program and vaccine coverage data. Of 1,199 sera, 1035 (86.3%, 95% confidence interval (CI) 84.4, 88.2) were above the measles threshold for protection, 70 (5.8%, 95% CI 4.5, 7.2) were equivocal and 94 (7.8%, 95% CI 6.3, 9.4) were negative. The proportion of positive sera was highest for those 1-5 years, with 180/199 (90.5%, 95% CI 86.4, 94.5) positive sera, and lowest for those age 12-19 years, at 158/199 (79.4%, 95% CI 73.8, 85.0). Adjusted for age, females were more likely than males to have antibody titers above the threshold of protection (odds ratio = 1.60, 95% CI 1.14, 2.24). Most of the study cohort were eligible for two measles vaccine doses, and vaccine uptake in Ontario is >90% for school-aged cohorts. We observed a higher than expected proportion of sera with antibody levels below the threshold of protection, suggesting that immunity in some Ontario age-groups may be waning, despite high vaccine coverage. Alternatively, the traditional measles correlates of protection may not be an appropriate measure of population protection in measles-eliminated settings.

Indexed as

Epidemiological MonitoringAdolescentAdultAntibodies, ViralChildChild, PreschoolCohort StudiesFemaleHumansImmunizationImmunoenzyme TechniquesInfantMaleMeaslesMeasles VaccineRisk FactorsAntibodies, ViralMeasles VaccineCanadaherd immunityMeaslesmeasles immunityOntariosero-epidemiologythreshold of protection

Identifiers

PMID31184979
PMCPMC6930091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.